-
公开(公告)号：EP0735863B1
公开(公告)日：2002-11-13
申请号：EP95906146.6
申请日：1994-12-22
发明人： CINCOTTA, Anthony N. , CINCOTTA, Manuel, Jr. , TIGNER, Susan Louise , RUNICE, Christopher Eric , PELLONI, Christopher Louis
IPC分类号： A61K9/20 , A61K31/44 , A61K31/495 , A61K31/48
CPC分类号： A61K31/4985 , A61K9/2013 , A61K31/00 , A61K31/475 , A61K31/48 , A61K45/06
摘要： Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90 % in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 °C and is useful for adjusting the plasma prolactin profile of a patient.
-
2.发明公开
公开(公告)号：EP0828492A1
公开(公告)日：1998-03-18
申请号：EP96921645.0
申请日：1996-05-30
CPC分类号： A61K31/166 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/165 , A61K31/405 , A61K31/44 , A61K31/48 , A61K31/495 , A61K31/40 , A61K2300/00
摘要： The present invention relates to method for reducing stenosis after non-bypass invasive intervention. The invention also relates to methods for ameliorating symptomatic chest pains following non-bypass invasive intervention. The method comprises administering a daily amount of a dopamine-potentiating/prolectin-reducing comound at a predetermined time and continuing administration for a period of time at least sufficient to permit the vascular injury to heal.
-
3.发明公开Accelerated release composition containing bromocriptine 失效Bromocriptin enthaltende Zusammensetzung mit beschleunigter Freisetzung
公开(公告)号：EP1258245A2
公开(公告)日：2002-11-20
申请号：EP02018888.4
申请日：1994-12-22
发明人： Cincotta, Anthony N. , Tigner, Susan Louise , Pelloni, Christopher Louis , Cincotta, Manuel, Jr. , Runice, Christopher Eric
CPC分类号： A61K31/4985 , A61K9/2013 , A61K31/00 , A61K31/475 , A61K31/48 , A61K45/06
摘要： Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37°C and is useful for adjusting the plasma prolactin profile of a patient.
摘要翻译： 本文公开了包含溴隐亭和一种或多种药学上可接受的赋形剂的固体口服剂型。 口服剂型在37℃在500ml 0.1N HCl水性介质中在5分钟内具有超过90％的溶解速率，并且可用于调节患者的血浆催乳素特征。
-
公开(公告)号：EP1258245A3
公开(公告)日：2003-01-02
申请号：EP02018888.4
申请日：1994-12-22
发明人： Cincotta, Anthony N. , Tigner, Susan Louise , Pelloni, Christopher Louis , Cincotta, Manuel, Jr. , Runice, Christopher Eric
CPC分类号： A61K31/4985 , A61K9/2013 , A61K31/00 , A61K31/475 , A61K31/48 , A61K45/06
摘要： Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37°C and is useful for adjusting the plasma prolactin profile of a patient.
-
5.发明公开METHOD FOR REGULATING METABOLISM WITH DOPAMINE BETA HYDROXYLASE INHIBITORS 失效方法调节代谢与多巴胺BETA HYDROXYLASEINHIBITOREN的
公开(公告)号：EP0836445A1
公开(公告)日：1998-04-22
申请号：EP96922476.0
申请日：1996-06-05
申请人： THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE , ERGO SCIENCE INCORPORATED
CPC分类号： A61K31/135 , A61K31/00 , A61K31/015 , A61K31/03 , A61K31/05 , A61K31/137 , A61K31/145 , A61K31/27 , A61K31/275 , A61K31/277 , A61K31/325 , A61K31/381 , A61K31/44 , Y10S514/824 , Y10S514/866
摘要： Disclosed herein are methods for regulating or ameliorating lipid and glucose metabolism and reducing in a vertebrate animal body fat stores, insulin resistance, hyperinsulinemia, hyperglycemia, hyperlipidemia, elevated blood lipoproteins (such as triglycerides and cholesterol including chylomicrons, VLDL and LDL) and/or increasing in the subject the plasma HDL. The methods comprise administration or timed administration of inhibitors or dopamine beta hydroxylase (DBH).
-
公开(公告)号：EP0833636A1
公开(公告)日：1998-04-08
申请号：EP96922478.0
申请日：1996-06-05
申请人： ERGO SCIENCE INCORPORATED , THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
CPC分类号： A61K31/166 , A61K31/4045 , A61K31/405 , A61K31/454 , A61K31/48 , A61K38/2257 , A61K31/40 , A61K2300/00
摘要： This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.
-
公开(公告)号：EP0833625A1
公开(公告)日：1998-04-08
申请号：EP96919438.0
申请日：1996-06-05
申请人： ERGO SCIENCE INCORPORATED , THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
CPC分类号： A61K31/13 , A61K31/16 , Y10S514/866
摘要： This invention relates to a method for modifying metabolism in a vertebrate animal which entails the administration of pantethine or cysteamine at a predetermined time daily. The method is useful in the treatment of hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia.
-
8.发明公开IMPROVED METHODS FOR THE DETERMINATION AND ADJUSTMENT OF PROLACTIN DAILY RHYTHMS 失效法确定和设置THE DAY催乳素节律紊乱
公开(公告)号：EP0769148A1
公开(公告)日：1997-04-23
申请号：EP95926737.0
申请日：1995-06-23
申请人： ERGO SCIENCE INCORPORATED , THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
CPC分类号： A61K31/4985 , A61K31/00 , A61K31/475 , A61K45/06 , G01N33/74
摘要： Disclosed are methods for detecting and adjusting abnormalities in prolactin daily rhythms. Provided is a method comparing a prolactin profile of a vertebrate subject to the prolactin profile of other vertebrate subjects having a normal prolactin profile; and adjusting the prolactin profile of the subject to cause the profile of the subject to conform to (or approach) the normal prolactin profile. Also provided is a method for evaluating the daily prolactin profile of a human subject wherein the method provides for comparing a set of at least two prolactin levels of the human and comparing them to corresponding prolactin levels for healthy humans (or a preestablished average prolactin curve for healthy humans) at the same time points. The method also provides for determining whether a human subject has an abnormal prolactin profile.
-
9.发明公开ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS 失效哌仑西平，甲基东及其他毒蕈碱受体拮抗剂的脂质代谢紊乱的治疗管理
公开(公告)号：EP0764026A1
公开(公告)日：1997-03-26
申请号：EP95927259.0
申请日：1995-06-20
申请人： ERGO SCIENCE INCORPORATED , BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
CPC分类号： A61K31/439 , A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , G01N33/74 , Y10S514/824 , Y10S514/866 , A61K2300/00
摘要： Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.
-
10.发明公开IMPROVED PROCESS FOR THE LONG TERM REDUCTION OF BODY FAT STORES, INSULIN RESISTANCE, HYPERINSULINEMIA AND HYPERGLYCEMIA IN VERTEBRATES 失效改进方法体脂STORE胰岛素抵抗，高胰岛素血症和高血糖脊椎动物长期减少。
公开(公告)号：EP0591458A1
公开(公告)日：1994-04-13
申请号：EP92915581.0
申请日：1992-06-24
申请人： THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE , ERGO SCIENCE INCORPORATED
CPC分类号： G01N33/74 , A61K31/00 , A61K31/13 , A61K31/137 , A61K31/15 , A61K31/166 , A61K31/195 , A61K31/221 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/405 , A61K31/435 , A61K31/439 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/46 , A61K31/475 , A61K31/48 , A61K31/496 , A61K31/4985 , A61K31/54 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K38/2257 , A61K45/06 , Y10S514/866 , Y10S514/909 , A61K31/165 , A61K2300/00
摘要： Procédé de modification et de régulation à long terme du métabolisme des lipides et du glucose - généralement afin de réduire l'obésité, l'insulinorésistance et l'hyperinsulinémie ou l'hyperglycémie, ou les deux (ces phénomènes constituant les marques du diabète non insulinodépendant ou du type II) - par administration à un vertébré, animal ou homme, d'un agoniste de dopamine et d'un stimulateur de prolactine. On administre l'agoniste de dopamine et le stimulateur de prolactine en posologie quotidienne, respectivement, à une heure du jour dépendant du rythme circadien normal des membres gros et maigres d'une espèce similaire. Les diminutions des dépôts de graisse dans le corps résultent du traitement d'une espèce obèse dans une séquence programmée quotidiennement sur la base de rythme circadien de la prolactine atteignant son maximum, ou de la prolactine et de glucocorticostéroïde atteignant leur maximum, et du niveau sanguin établi pour des membres maigres sensibles à l'insuline d'une espèce similaire. On administre l'agoniste de dopamine au moment ou juste après le moment correspondant à la concentration maximum de prolactine dans le plasma rencontrée chez des animaux maigres de la même espèce, et on administre le stimulateur de prolactine juste avant que le rythme de la prolactine dans le plasma n'atteigne son maximum chez des animaux maigres. On peut également maîtriser l'insulinorésistance, et l'hyperinsulinémie ou l'hyperglycémie ou les deux, chez l'homme sur une base à long terme par un traitement correspondant à celui du traitement de l'obésité. Les injections quotidiennes à court terme réétablissent un rythme hormonal dans le centre nerveux du cerveau afin de produire des effets à long terme.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
